Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma

Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer globally. However, the survival rate of lung adenocarcinoma patients remains low. Immune checkpoints and long noncoding RNAs are emerging as vital tools for predicting the immunotherapeutic response and outcomes of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hongpan, Liu, Meihan, Yang, Zhihao, Du, Guobo, Yu, Bin, Gui, Yan, Cao, Lu, Li, Xianfu, Tan, Bangxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329438/
https://www.ncbi.nlm.nih.gov/pubmed/35896612
http://dx.doi.org/10.1038/s41598-022-16715-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329438/
https://www.ncbi.nlm.nih.gov/pubmed/35896612
http://dx.doi.org/10.1038/s41598-022-16715-0

Ejemplares similares